Roblox founder and CEO David Baszucki and his wife, Jan Ellison Baszucki, have awarded a $20 million grant to establish a new clinical and research facility focused on metabolic psychiatry at McLean Hospital in Belmont, Massachusetts. Announced on October 21, 2026, through the couple's philanthropic organization, the Baszucki Group, the funding creates the McLean Center for Metabolic Psychiatry. The center will examine how nutrition, energy metabolism, and diet-based interventions—such as medically supervised ketogenic therapy—affect severe mental illnesses including bipolar disorder, schizophrenia, and depression.

The initiative stems from the Baszucki family's personal experience with their now 30-year-old son, Matthew Baszucki, who was diagnosed with bipolar disorder. According to VPM / NPR, the new facility at McLean, a member of the Mass General Brigham healthcare system, is the first of its kind in the United States and will serve as the anchor for the newly launched Global Network for the Advancement of Metabolic Psychiatry (MetPsy).

A Personal Crisis Turns Into Philanthropic Action

Before shifting their philanthropic focus toward metabolic health, the Baszucki family spent years seeking effective care for their son. Public accounts shared by the family detail a difficult period involving psychiatric hospitalizations, consultations with dozens of mental healthcare providers, and prescriptions for more than a dozen different medications. At one point during his illness, Matthew left home in a psychotic state and slept on the streets of Los Angeles.

Searching for options, Jan Ellison Baszucki contacted Harvard psychiatrist Dr. Chris Palmer after hearing him discuss ketogenic therapy for bipolar disorder on a podcast. "A part of me prepared to say, 'I can't talk to you because I'm not taking new patients,' and I'm really glad I took the call instead," Palmer recalled in an interview with VPM / NPR.

In January 2021, Matthew began a medically supervised ketogenic diet with clinical support. High in fat and low in carbohydrates, the ketogenic diet has been used by physicians for decades to manage treatment-resistant epilepsy, as it alters how the body and brain process energy. After roughly four months on the regimen, Matthew reported significant improvements during a June appearance on the Metabolic Mind podcast, an informational platform founded by his family. He noted that his sleep stabilized and he stopped experiencing episodes of mania and delusion. "My brain felt like it could work again," Matthew said, adding that he was able to begin a gradual, supervised process of tapering his medications.

This personal turnaround has driven major financial commitments from the family. According to Inside Philanthropy, the Baszuckis previously joined Google co-founder Sergey Brin and investor Kent Dauten in 2022 in a combined $150 million commitment toward bipolar disorder research and treatment, followed by additional backing for specific clinical trials and metabolic projects.

Understanding Metabolic Psychiatry

While some media coverage, such as a report from The Times of India, specifically highlights the $20 million grant's connection to bipolar disorder and diet-based therapies, institutional statements and coverage from The Boston Globe clarify that the center's mandate spans multiple serious psychiatric conditions. The core premise of metabolic psychiatry is that severe mental illnesses may be linked to how the brain produces and utilizes energy.

Dr. Dost Öngür, director of the new McLean center and chief of the hospital's psychotic disorders division, explained the underlying science to The Boston Globe. "The brain actually is the most energy-hungry organ in our bodies. It burns the most energy, gram for gram, of any of our organs," Öngür said. He noted that energy supports brain cells as they process information and generate behavior, and that research over the past decade has identified abnormalities in brain energy production and utilization among patients with conditions like schizophrenia and bipolar disorder.

"Until recently, we haven't really appreciated the importance of this for psychiatric disorders," Öngür stated. "But now we have this growing awareness that energy has to be in good supply and at the places where the brain needs it. If that doesn't happen, that can lead to problems." Correcting those metabolic issues through targeted therapies, he noted, offers a potential pathway to improve psychiatric symptoms.

What This Means for Patients and Clinical Care

Despite the growing interest in nutritional interventions, psychiatrists emphasize that dietary therapies are not a standalone cure or a replacement for established medical care. While the institutional announcement via Business Wire highlights a growing body of preliminary research supporting metabolic approaches, independent clinical experts stress that rigorous, controlled trials are still required to prove efficacy.

According to The Boston Globe, McLean clinicians view ketogenic therapy as a potential add-on to mainstream psychiatric treatment, conducted strictly under the supervision of healthcare professionals. The $20 million investment will fund clinical care, professional training, public education, and controlled clinical trials designed to gather hard evidence on which metabolic interventions work best for specific patient populations.

What independent evidence supports these interventions, and when should patients consult clinicians?

While small-scale studies and case reports suggest that ketogenic diets and metabolic therapies may reduce symptoms in some patients with depression, bipolar disorder, and schizophrenia, large-scale randomized controlled trials are still underway. Because strict dietary changes like the ketogenic diet cause significant shifts in body chemistry and can interact with psychiatric medications, patients should never alter their diet or adjust their medication regimens without consulting their prescribing physician and a qualified clinical care team.

How will researchers separate diet effects from other factors?

A central goal of the McLean Center for Metabolic Psychiatry is to conduct structured clinical trials. By establishing standardized research protocols within an academic hospital setting, investigators aim to measure specific metabolic biomarkers and psychiatric outcomes, allowing them to distinguish the biological impact of dietary interventions from medication adjustments, increased clinical attention, or placebo effects.

Will the program serve patients beyond McLean Hospital?

While direct clinical care and in-person trials will take place at McLean Hospital in Massachusetts, the center is designed to anchor the Global Network for the Advancement of Metabolic Psychiatry. Through its education and training pillars, the initiative aims to share clinical protocols, trial data, and training resources with healthcare providers internationally to expand access to safe, supervised care.

Sources